The program's process focuses on early detection, diagnosis, treatment and treatment monitoring, and patient follow up. Critical in the program's standard of care is ensuring all patients receive molecular testing, which uses DNA, RNA and proteins to test for specific states of disease. In lung cancer, molecular testing is used to determine potential patient response to targeted therapy.The LCF has received generous support from a number of distinguished industry partners, including GE Healthcare, Pfizer and Boehringer-Ingelheim. GE Healthcare provided in-kind services from its oncology solutions division to help create the program's flow and metrics. The LCF is working with Boehringer-Ingelheim and Pfizer in partnership to broaden the overall awareness of multi-disciplinary collaborations that incorporate personalized testing to initiate timely and appropriate lung cancer treatments. Boehringer-Ingelheim also leads the letstestnow.com campaign, set up to improve patient outcomes through a multidisciplinary approach to biomarker testing in advanced non-small cell lung cancer.
- In the last 45 years 50 million people worldwide have died from lung cancer.
- Every day 450 more die, 19 every hour and one every three minutes will die in the US and 1.4 million worldwide every year.
- It is the leading cancer killer in every ethnic group, and since 1987 lung cancer has killed more women every year than breast cancer.
- Yet the five-year survival rate for lung cancer is only 15.7 percent, and it has remained unchanged for more than 40 years.
- This staggering loss of life has gone unnoticed too long, and the Bonnie J. Addario Lung Cancer Foundation is on a mission to change that.
- The LCF funds clinical research that leads to life-saving discoveries and treatments and provides critical support services and educational programs to empower patients and create hope.